がん免疫療法の世界市場2014-2025:製品別(モノクローナル抗体、免疫調節剤、腫瘍溶解性ウイルス療法、がんワクチン)、がんのタイプ別

Grand View Researchが発行した調査報告書(GVIEW801011)
◆英語タイトル:Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025
◆商品コード:GVIEW801011
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2017年10月5日
◆ページ数:75
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:化学
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、がん免疫療法の世界市場について調査・分析し、がん免疫療法の世界市場動向、がん免疫療法の世界市場規模、市場予測、セグメント別がん免疫療法市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing patient pool and higher mortality rate are boosting the need for cancer immunotherapy globally. However, lack of awareness and adverse effects associated with immune therapeutic drugs are restraining market growth.
Cancer immunotherapy has been emerging as a new avenue for revenue generation for pharmaceutical companies. In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting demand for immunotherapy. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is expected to initiate introduction of advanced therapeutics in the market.

Furthermore, increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Increasing investments in R&D pertaining to use of monoclonal bodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have resulted in discovery of new therapeutic options for cancer treatment. Technological advancements, such as radiation and nanoparticle therapies, are boosting the cancer immunotherapy market. Majority of cancer immunotherapy drugs have been used in treatment of non-small cell lung cancer, breast cancer, and prostate cancer.

Further Key Findings from the Report Suggest:

• Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy

• Lung cancer accounted for the largest share in the cancer type segment owing to rise in demand for immunotherapeutic drugs in its treatment

• North America dominated the market with the largest share in 2016. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period

• Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective cancer treatment

• Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc. dominated the global cancer immunotherapy market.

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
1.3 Approaches for market estimation
1.3.1 Approach 1: Demand Analysis & Bottom up Approach
1.3.2 Approach 2: Top down market estimation
1.3.3 Approach 3: Commodity flow and bottom up market estimation
1.3.4 Approach 4: KoL perspective based market sizing
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Cancer Immunitherapy Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Cancer Immunotherapy Market – SWOT Analysis, By Factor (political & legal, economic and technological)
3.5 Industry Analysis – Porter’s
3.5.1 Threat of new entrants
3.5.2 Competitive Rivalry
3.5.3 Bargaining power of suppliers
3.5.4 Bargaining power of buyers
3.5.5 Threat of substitutes
3.6 Pipeline Analysis, By Key Company, 2016
Chapter 4 Cancer Immunotherapy Market: Product Estimates & Trend Analysis
4.1 Cancer Immunotherapy Market: Product movement analysis
4.2 Monoclonal Antibodies
4.2.1 Market Estimates and Forecast, 2014 – 2024 (USD Billion)
4.3 Immunomodulators
4.3.1 Market Estimates and Forecast, 2014 – 2024 (USD Billion)
4.4 Oncolytic viral therapies and cancer vaccines
4.4.1 Market Estimates and Forecast, 2014 – 2024 (USD Billion)
Chapter 5 Cancer Immunotherapy Market : Cancer Type Estimates and Trend Analysis
5.1 Cancer immunotherapy market: Application movement analysis
5.2 Lung cancer
5.2.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.3 Breast cancer
5.3.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.4 Colorectal cancer
5.4.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.5 Melanoma
5.5.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.6 Prostate cancer
5.6.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.7 Head and neck cancer
5.7.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
5.8 Ovarian cancer
5.8.1 Market Estimates and Forecast, 2014 – 2025 (USD Billion)
Chapter 6 Regional Estimates & Trend Analysis, by Product and Cancer Type
6.1 Cancer Immunotherapy Market: Regional movement analysis
6.2 North America
6.2.1 U.S.
6.2.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.2.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.2.2 Canada
6.2.2.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.2.2.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.3 Europe
6.3.1 U.K.
6.2.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.3.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.3.2 Germany
6.2.2.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.3.2.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 China
6.4.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.4.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.4.2 Japan
6.4.2.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.4.2.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.5 Latin America
6.5.1 Brazil
6.5.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.5.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.5.2 Mexico
6.5.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.5.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
6.6 Middle East and Africa (MEA)
6.6.1 South Africa
6.6.1.1 Market Estimates and Forecast, by Product, 2014 – 2025 (USD Billion)
6.6.1.2 Market Estimates and Forecast, by Cancer Type, 2014 – 2025 (USD Billion)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Company Profiles
7.3 AstraZeneca
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Geographic Footprint
7.3.4 Product Benchmarking
7.3.5 Strategic Initiatives
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Geographic Footprint
7.4.4 Product Benchmarking
7.4.5 Strategic Initiatives
7.5 F. Hoffman-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Geographic Footprint
7.5.4 Product Benchmarking
7.5.5 Strategic Initiatives
7.6 Bristol-Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Geographic Footprint
7.6.4 Product Benchmarking
7.6.5 Strategic Initiatives
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Geographic Footprint
7.7.4 Product Benchmarking
7.7.5 Strategic Initiatives
7.8 Merck & Co., Inc.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Geographic Footprint
7.8.4 Product Benchmarking
7.8 5 Strategic Initiatives
7.9 Pfizer Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Geographic Footprint
7.9.4 Product Benchmarking
7.9.5 Strategic Initiatives

List of Tables

TABLE 1 North America Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 2 North America Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 3 U.S. Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 4 U.S. Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 5 Canada Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 6 Canada Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 7 Europe Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 8 Europe Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 9 U.K. Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 10 U.K. Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 11 Germany Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 12 Germany Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 13 Asia Pacific Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 14 Asia Pacific Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 15 Japan Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 16 Japan Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 17 China Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 18 China Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 19 Latin America Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 20 Latin America Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 21 Brazil Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 22 Brazil Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 23 Mexico Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 24 Mexico Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 25 MEA Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 26 MEA Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
TABLE 27 South AfircaCancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
TABLE 28 South Africa Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Cancer Immunotherapy Market: Product movement analysis
FIG. 15 Monoclonal antibodies market, 2014 - 2025 (USD Million)
FIG. 16 Immunomodulators market, 2014 - 2025 (USD Million)
FIG. 17 Oncolytic viral therapies and cancer vaccines market, 2014 - 2025 (USD Million)
FIG. 18 Cancer Immunotherapy Market: Application movement analysis
FIG. 19 Lung cancer market, 2014- 2025 (USD Million)
FIG. 20 Breast cancer market, 2014 - 2025 (USD Million)
FIG. 21 Colorectal cancer market, 2014 - 2025 (USD Million)
FIG. 22 Melanoma market, 2014 - 2025 (USD Million)
FIG. 23 Prostate cancer market, 2014- 2025 (USD Million)
FIG. 24 Head and Neck cancer market, 2014 - 2025 (USD Million)
FIG. 25 Ovarian cancer market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Cancer Immunotherapy Market: regional movement analysis
FIG. 28 Germany cancer prevalence, incidence and mortality rate:
FIG. 29 Strategy framework

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん免疫療法の世界市場2014-2025:製品別(モノクローナル抗体、免疫調節剤、腫瘍溶解性ウイルス療法、がんワクチン)、がんのタイプ別(Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆